Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2026)

Acadia Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• In Q1 2026, Operating Leases fell 12.62% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $39.0 million (down 12.62% YoY), while the FY2025 annual figure was $40.6 million, down 3.53% from the prior year.
• Operating Leases was $39.0 million for Q1 2026 at Acadia Pharmaceuticals, down from $40.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $55.5 million in Q1 2022 to a low of $39.0 million in Q1 2026.
• Historically, Operating Leases has averaged $47.3 million across 5 years, with a median of $47.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Leases dropped 15.97% in 2024, then gained 6.44% in 2025.
• A 5-year view of Operating Leases shows it stood at $52.7 million in 2022, then slipped by 9.29% to $47.8 million in 2023, then fell by 12.06% to $42.0 million in 2024, then slipped by 3.53% to $40.6 million in 2025, then dropped by 3.82% to $39.0 million in 2026.
• The last three Operating Leases figures came in at $39.0 million (Q1 2026), $40.6 million (Q4 2025), and $43.0 million (Q3 2025), per Business Quant data.